Primary Graft Dysfunction: Definition, Risk Factors, Short- and Long-Term Outcomes

ABSTRACT

Primary graft dysfunction (PGD) is a form of early lung graft dysfunction that is a major cause of early morbidity and mortality following lung transplantation. Survivors of PGD have decreased long-term lung function and an increased risk of developing bronchiolitis obliterans syndrome (BOS), a manifestation of chronic graft dysfunction. This article reviews the current definition, contributing factors, and guidelines for grading clinical PGD, as well as controversies surrounding them. The current literature examining clinical risk factors for PGD is summarized, as are studies exploring molecular and biochemical markers for PGD prediction and severity. Studies examining the short- and long-term effects of PGD on lung transplant outcomes are reviewed. Lastly, we highlight the emerging concepts in lung transplantation that will potentially impact PGD incidence and outcomes.

KEYWORDS

Primary graft dysfunction - ischemia-reperfusion injury - lung transplantation

REFERENCES

• 1 Christie J D, Bavaria J E, Palevsky H I et al.. Primary graft failure following lung transplantation.  Chest. 1998;  114 51-60
• 2 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.  Ann Thorac Surg. 2000;  69 1681-1685
• 3 Christie J D, Kotloff R M, Pochettino A et al.. Clinical risk factors for primary graft failure following lung transplantation.  Chest. 2003;  124 1232-1241
• 4 Arcasoy S M, Kotloff R M. Lung transplantation.  N Engl J Med. 1999;  340 1081-1091
• 5 Christie J D, Van Raemdonck D, de Perrot M ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods.  J Heart Lung Transplant. 2005;  24 1451-1453
• 6 Arcasoy S M, Fisher A, Hachem R R, Scavuzzo M, Ware L B. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes.  J Heart Lung Transplant. 2005;  24 1483-1488
• 7 Christie J D, Kotloff R M, Ahya V N et al.. The effect of primary graft dysfunction on survival after lung transplantation.  Am J Respir Crit Care Med. 2005;  171 1312-1316
• 8 Christie J D, Carby M, Bag R, Corris P, Hertz M, Weill D. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2005;  24 1454-1459
• 9 Daud S A, Yusen R D, Meyers B F et al.. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.  Am J Respir Crit Care Med. 2007;  175 507-513
• 10 Barr M L, Kawut S M, Whelan T P ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, IV: Recipient-related risk factors and markers.  J Heart Lung Transplant. 2005;  24 1468-1482
• 11 Whitson B A, Nath D S, Johnson A C et al.. Risk factors for primary graft dysfunction after lung transplantation.  J Thorac Cardiovasc Surg. 2006;  131 73-80
• 12 Prekker M E, Nath D S, Walker A R et al.. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation.  J Heart Lung Transplant. 2006;  25 371-378
• 13 Prekker M E, Herrington C S, Hertz M I, Radosevich D M, Dahlberg P S. Early trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction.  Chest. 2007;  132 991-997
• 14 Oto T, Levvey B J, Snell G I. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system.  J Heart Lung Transplant. 2007;  26 431-436
• 15 Christie J, Keshavjee S, Orens J ISHLT Working Group on PGD et al. Potential refinements of the International Society for Heart and Lung Transplantation primary graft dysfunction grading system.  J Heart Lung Transplant. 2008;  27 138
• 16 Oto T, Griffiths A P, Levvey B J, Pilcher D V, Williams T J, Snell G I. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation.  J Thorac Cardiovasc Surg. 2006;  132 140-147
• 17 de Perrot M, Liu M, Waddell T K, Keshavjee S. Ischemia-reperfusion-induced lung injury.  Am J Respir Crit Care Med. 2003;  167 490-511
• 18 Carter Y M, Gelman A E, Kreisel D. Pathogenesis, management, and consequences of primary graft dysfunction.  Semin Thorac Cardiovasc Surg. 2008;  20 165-172
• 19 Frank M M. Complement in the pathophysiology of human disease.  N Engl J Med. 1987;  316 1525-1530
• 20 de Perrot M, Bonser R S, Dark J ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, III: Donor-related risk factors and markers.  J Heart Lung Transplant. 2005;  24 1460-1467
• 21 Lee J C, Christie J D. Primary graft dysfunction.  Proc Am Thorac Soc. 2009;  6 39-46
• 22 Meyer D M, Bennett L E, Novick R J, Hosenpud J D. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation.  Chest. 2000;  118 1255-1262
• 23 Oto T, Griffiths A P, Levvey B et al.. A donor history of smoking affects early but not late outcome in lung transplantation.  Transplantation. 2004;  78 599-606
• 24 Lee J CKC, Hadjiliadis D, Aahya V N et al.. Risk factors for early vs late primary graft dysfunction [abstract].  Am J Respir Crit Care Med. 2008;  177 A396
• 25 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.  Ann Thorac Surg. 2000;  69 1681-1685
• 26 Thabut G, Vinatier I, Stern J B et al.. Primary graft failure following lung transplantation: predictive factors of mortality.  Chest. 2002;  121 1876-1882
• 27 Covarrubias M, Ware L B, Kawut S M Lung Transplant Outcomes Group et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.  Am J Transplant. 2007;  7 2573-2578
• 28 Kawut S M, Okun J, Shimbo D et al.. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation.  Chest. 2009;  136 237-244
• 29 Lee J C, Kuntz C, Kawut S M et al.. Clinical risk factors for the development of primary graft dysfunction [abstract].  J Heart Lung Transplant. 2008;  27 S67-S68
• 30 Cassivi S D, Meyers B F, Battafarano R J et al.. Thirteen-year experience in lung transplantation for emphysema.  Ann Thorac Surg. 2002;  74 1663-1669 discussion 1669-1670
• 31 Fiser S M, Kron I L, McLendon Long S, Kaza A K, Kern J A, Tribble C G. Early intervention after severe oxygenation index elevation improves survival following lung transplantation.  J Heart Lung Transplant. 2001;  20 631-636
• 32 Hadjiliadis D, Chaparro C, Reinsmoen N L et al.. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study.  J Heart Lung Transplant. 2005;  24(7, Suppl) S249-S254
• 33 Yoshida S, Haque A, Mizobuchi T et al.. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants.  Am J Transplant. 2006;  6 724-735
• 34 Bobadilla J L, Love R B, Jankowska-Gan E et al.. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation.  Am J Respir Crit Care Med. 2008;  177 660-668
• 35 Sommers K E, Griffith B P, Hardesty R L, Keenan R J. Early lung allograft function in twin recipients from the same donor: risk factor analysis.  Ann Thorac Surg. 1996;  62 784-790
• 36 Szeto W Y, Kreisel D, Karakousis G C et al.. Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome.  J Thorac Cardiovasc Surg. 2002;  124 241-249
• 37 Wang Y, Kurichi J E, Blumenthal N P et al.. Multiple variables affecting blood usage in lung transplantation.  J Heart Lung Transplant. 2006;  25 533-538
• 38 Webert K E, Blajchman M A. Transfusion-related acute lung injury.  Transfus Med Rev. 2003;  17 252-262
• 39 Christie J D, Shah C V, Kawut S M Lung Transplant Outcomes Group et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.  Am J Respir Crit Care Med. 2009;  180 1010-1015
• 40 dos Santos C C, Okutani D, Hu P et al.. Differential gene profiling in acute lung injury identifies injury-specific gene expression.  Crit Care Med. 2008;  36 855-865
• 41 Li J, Nie J, Chen G et al.. Gene expression profile of pulmonary tissues in different phases of lung ischemia-reperfusion injury in rats.  J Huazhong Univ Sci Technolog Med Sci. 2007;  27 564-570
• 42 Ray M, Dharmarajan S, Freudenberg J, Zhang W, Patterson G A. Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation.  Am J Transplant. 2007;  7 2396-2405
• 43 Anraku M, Cameron M J, Waddell T K et al.. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study.  Am J Transplant. 2008;  8 2140-2148
• 44 Kaneda H, Waddell T K, de Perrot M et al.. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans.  Am J Transplant. 2006;  6 544-551
• 45 Calfee C S, Budev M M, Matthay M A et al.. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation.  J Heart Lung Transplant. 2007;  26 675-680
• 46 Kawut S M, Okun J, Shimbo D Lung Transplant Outcomes Group et al. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.  Chest. 2009;  136 237-244
• 47 Hoffman S A, Wang L, Shah C V Lung Transplant Outcomes Group et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.  Am J Transplant. 2009;  9 389-396
• 48 Fisher A J, Donnelly S C, Hirani N et al.. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation.  Am J Respir Crit Care Med. 2001;  163 259-265
• 49 De Perrot M, Sekine Y, Fischer S et al.. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation.  Am J Respir Crit Care Med. 2002;  165 211-215
• 50 Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, Aharinejad S. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction.  Am J Transplant. 2007;  7 700-706
• 51 Christie J D, Robinson N, Ware L B et al.. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.  Am J Respir Crit Care Med. 2007;  175 69-74
• 52 Justice A C, Covinsky K E, Berlin J A. Assessing the generalizability of prognostic information.  Ann Intern Med. 1999;  130 515-524
• 53 Khan S U, Salloum J, O'Donovan P B et al.. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response.  Chest. 1999;  116 187-194
• 54 Burton C M, Iversen M, Milman N et al.. Outcome of lung transplanted patients with primary graft dysfunction.  Eur J Cardiothorac Surg. 2007;  31 75-82
• 55 Whitson B A, Prekker M E, Herrington C S et al.. Primary graft dysfunction and long-term pulmonary function after lung transplantation.  J Heart Lung Transplant. 2007;  26 1004-1011
• 56 Christie J D, Sager J S, Kimmel S E et al.. Impact of primary graft failure on outcomes following lung transplantation.  Chest. 2005;  127 161-165
• 57 Fiser S M, Tribble C G, Long S M et al.. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.  Ann Thorac Surg. 2002;  73 1041-1047 discussion 1047-1048
• 58 Fisher A J, Wardle J, Dark J H, Corris P A. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS).  J Heart Lung Transplant. 2002;  21 1206-1212
• 59 Girgis R E, Tu I, Berry G J et al.. Risk factors for the development of obliterative bronchiolitis after lung transplantation.  J Heart Lung Transplant. 1996;  15 1200-1208
• 60 Hachem R R, Khalifah A P, Chakinala M M et al.. The significance of a single episode of minimal acute rejection after lung transplantation.  Transplantation. 2005;  80 1406-1413
• 61 Khalifah A P, Hachem R R, Chakinala M M et al.. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome.  Am J Transplant. 2005;  5 2022-2030
• 62 Huang H J, Yusen R D, Meyers B F et al.. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome.  Am J Transplant. 2008;  8 2454-2462
• 63 Halloran P F, Homik J, Goes N et al.. The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes.  Transplant Proc. 1997;  29 79-81
• 64 Bharat A, Kuo E, Steward N et al.. Immunological link between primary graft dysfunction and chronic lung allograft rejection.  Ann Thorac Surg. 2008;  86 189-195 discussion 196-197
• 65 Burlingham W J, Love R B, Jankowska-Gan E et al.. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.  J Clin Invest. 2007;  117 3498-3506
• 66 Hornby K, Ross H, Keshavjee S, Rao V, Shemie S D. Non-utilization of hearts and lungs after consent for donation: a Canadian multicentre study.  Can J Anaesth. 2006;  53 831-837
• 67 Ware L B, Wang Y, Fang X et al.. Assessment of lungs rejected for transplantation and implications for donor selection.  Lancet. 2002;  360 619-620
• 68 Oto T. Lung transplantation from donation after cardiac death (non-heart-beating) donors.  Gen Thorac Cardiovasc Surg. 2008;  56 533-538
• 69 Neyrinck A P, Van De Wauwer C, Geudens N et al.. Comparative study of donor lung injury in heart-beating versus non-heart-beating donors.  Eur J Cardiothorac Surg. 2006;  30 628-636
• 70 De Vleeschauwer S, Van Raemdonck D, Vanaudenaerde B et al.. Early outcome after lung transplantation from non-heart-beating donors is comparable to heart-beating donors.  J Heart Lung Transplant. 2009;  28 380-387
• 71 Inci I, Zhai W, Arni S et al.. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors.  J Heart Lung Transplant. 2007;  26 1054-1060
• 72 Loehe F, Preissler G, Annecke T, Bittmann I, Jauch K W, Messmer K. Continuous infusion of nitroglycerin improves pulmonary graft function of non-heart-beating donor lungs.  Transplantation. 2004;  77 1803-1808
• 73 Rega F R, Wuyts W A, Vanaudenaerde B M et al.. Nebulized N-acetyl cysteine protects the pulmonary graft inside the non-heart-beating donor.  J Heart Lung Transplant. 2005;  24 1369-1377
• 74 Cypel M, Yeung J C, Hirayama S et al.. Technique for prolonged normothermic ex vivo lung perfusion.  J Heart Lung Transplant. 2008;  27 1319-1325
• 75 Cypel M YJ, Liu M, Chen F et al.. Normothermic human ex vivo lung perfusion (EVLP) for improved assessment of extended criteria donor lungs for transplantation [abstract].  J Heart Lung Transplant. 2009;  28 S126